Literature DB >> 10070284

Survival of colorectal cancer patients in Europe during the period 1978-1989. EUROCARE Working Group.

G Gatta1, J Faivre, R Capocaccia, M Ponz de Leon.   

Abstract

This study concerns the survival of European patients diagnosed between 1978 and 1989 with colorectal cancer. Variations in survival in relation to age, country and period of diagnosis were examined. Data from the EUROCARE study were supplied by population-based cancer registries in 17 countries to a common protocol. Five years after diagnosis, relative survival rates were 47 and 43% for cancers of the colon and rectum, respectively. Survival decreased with increasing age: the relative risk of dying for the oldest patients (75+) was 1.39 for rectum and 1.54 for colon compared with the youngest patients (15-44 years). In 1985-1989 survival from colorectal cancer differed significantly between different European countries: the Nordic countries (Denmark excluded), The Netherlands, Switzerland, France and Austria were characterised by high survival, whilst Eastern European countries, the U.K. and Denmark were characterised by low survival. There was a general improvement in survival over the period 1978-1989: from 40 to 48% for colon cancer and 38 to 46% for rectal cancer. For neither cancer site did between-country survival differences narrow over the study period. Intercountry and time differences in survival differences are probably related to stage at diagnosis and postoperative mortality.

Entities:  

Mesh:

Year:  1998        PMID: 10070284     DOI: 10.1016/s0959-8049(98)00327-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  26 in total

Review 1.  Chemoradiotherapy for colorectal cancer.

Authors:  N Andre; W Schmiegel
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

2.  Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer.

Authors:  Wesam A Nasif; Mahmoud Lotfy; Ibrahim H El-Sayed; Ayman El-Meghawry El-Kenawy; Mohamed El-Shahat; Nabil Gad El-Hak
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.

Authors:  Javier Sastre; Cristina Grávalos; Fernando Rivera; Bartomeu Massuti; Manuel Valladares-Ayerbes; Eugenio Marcuello; José L Manzano; Manuel Benavides; Manuel Hidalgo; Eduardo Díaz-Rubio; Enrique Aranda
Journal:  Oncologist       Date:  2012-02-23

4.  The challenge of colorectal cancer prevention in Spain.

Authors:  Julio Lopez-Bastida; Begoña Bellas-Beceiro; Enrique Quintero-Carrión
Journal:  Eur J Health Econ       Date:  2010-01

5.  Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.

Authors:  J Feliu; M J Safont; A Salud; F Losa; C García-Girón; C Bosch; P Escudero; R López; C Madroñal; M Bolaños; M Gil; A Llombart; J Castro-Carpeño; M González-Barón
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 6.  Colorectal cancer, one entity or three.

Authors:  Feng-ying Li; Mao-de Lai
Journal:  J Zhejiang Univ Sci B       Date:  2009-03       Impact factor: 3.066

7.  Prognostic factors in 165 elderly colorectal cancer patients.

Authors:  Ke-Jun Nan; Hai-Xia Qin; Guang Yang
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

8.  An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics.

Authors:  Jie-Kai Yu; Yi-Ding Chen; Shu Zheng
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

Review 9.  Patterns of colorectal cancer care in Europe, Australia, and New Zealand.

Authors:  Neetu Chawla; Eboneé N Butler; Jennifer Lund; Joan L Warren; Linda C Harlan; K Robin Yabroff
Journal:  J Natl Cancer Inst Monogr       Date:  2013

10.  Colon cancer in France: evidence for improvement in management and survival.

Authors:  C Faivre-Finn; A-M Bouvier-Benhamiche; J M Phelip; S Manfredi; V Dancourt; J Faivre
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.